^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | garsorasib (D-1553) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study to Evaluate D-1553 in Subjects With Solid Tumors
Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
Source:
Title:
Study to Evaluate D-1553 in Subjects With Lung Cancer
Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
More C2 evidence
Source:
Title:
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
Excerpt:
...- Subject has KRasG12C mutation in tumor tissue or other biospecimens containing cancer cells or DNA....
Trial ID:
Less C2 evidence
Source:
Title:
1056 - Potent in vivo anti-tumor activity of D-1553 as a single agent and in combination with targeted therapeutics in a broad spectrum of patient-derived xenograft tumor models with KRas G12C mutation
Published date:
03/10/2021
Excerpt:
In the lung cancer PDX models, D-1553 exhibited tumor growth inhibition (TGI) from 43.6% to 124.3%, with 4 out of 8 models showing tumor regression. In the colorectal cancer PDX models, the range of TGI was from 60.9% to 105.7%, with 3 out of 9 models showing regression. Combination treatment of D-1553 with chemotherapy and targeted agents demonstrated enhanced anti-tumor activity resulting in more tumor regression compared to single agent treatment.
Secondary therapy:
Chemotherapy
Source:
Title:
932 - Discovery of D-1553, a novel and selective KRas-G12C Inhibitor with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Published date:
03/10/2021
Excerpt:
The anti-tumor activity of D-1553 is evaluated across a panel of cancer cell lines including lung, pancreatic and colorectal cancers and shown to be active only in cancer cells with KRas-G12C mutation....When D-1553 is combined with MEK inhibitor, SHP2 inhibitor or cytotoxic agents, further tumor growth inhibition or regression was observed in tumor xenograft models. These data suggest that D-1553 has anti-tumor activity in a broad spectrum of cancers and is suitable for tissue-agnostic clinical development targeting cancers with KRas-G12C mutation.
